GlaxoSmithKline (NYSE: GSK)‘s stock had its “underperform” rating reaffirmed by BNP Paribas in a research note issued on Wednesday.
Several other analysts have also recently commented on the stock. Analysts at Jefferies Group raised their price target on shares of GlaxoSmithKline from $1,500.00 to $1,550.00 in a research note to investors on Friday, February 22nd. They now have a “hold” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note to investors on Friday, February 8th. They now have a $48.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note to investors on Thursday, December 27th. They now have a $46.00 price target on the stock.
Ten investment analysts have rated the stock with a buy rating, one has assigned an overweight rating, seventeen have issued a hold rating, two have given an underweight rating, and two have issued a sell rating to the stock. The stock currently has a consensus rating of “hold” and a consensus target price of $46.65.
Shares of GlaxoSmithKline traded up 0.18% during mid-day trading on Wednesday, hitting $44.27. GlaxoSmithKline has a one year low of $41.68 and a one year high of $47.70. The stock’s 50-day moving average is currently $44.94. The company has a market cap of $106.8 billion and a P/E ratio of 15.02.
The company also recently announced a quarterly dividend, which is scheduled for Thursday, April 11th. Stockholders of record on Friday, February 22nd will be paid a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.62%. The ex-dividend date is Wednesday, February 20th.
GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
